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ABSTRACT
Introduction: Ovarian cancer (OC) diagnosis remains a clinical challenge due to lack of early symptoms and insufficient 
accuracy of the available diagnostic methods. The purpose of this study was to determine whether osteopontin could be 
useful in differential diagnosis of ovarian tumors.
Material and methods: Serum samples from 92 patients qualified for surgical treatment due to ovarian mass were divided 
into 2 groups according to the histopathological result: OC including borderline ovarian tumors (n = 39) and benign ovar-
ian tumors (BOTs) (n = 53). CA125, HE4 and osteopontin concentrations were measured in all patients. Areas under  the 
receiver operating characteristic curves (AUC of ROC) were used to compare the discriminative ability of the univariate 
and multivariate diagnostic models.
Results: The addition of osteopontin to ROMA significantly improved the diagnostic performance of the test in 3 of the 
5 analyses: 1) in the OC vs BOT group (from AUC of 0.955 to 0.975), 2) in premenopausal women OC vs BOT (from AUC of 
0.828 to 0.892) and 3) in the FIGO I-II stage OC vs BOT (from AUC of 0.865 to 0.895). It did not alter the diagnostic performance 
of multifactor tests in the group of postmenopausal women nor in OC FIGO III-IV stage group. Osteopontin was also the 
best single marker to differentiate between early stage OC and BOTs (AUC of 0.863).
Conclusions: Osteopontin improves the diagnostic performance of a multimarker OC  diagnostic test and could be useful 
in differential diagnosis of ovarian tumors, especially in pre-menopausal women and for early stage OC. 
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INTRODUCTION
Early and effective detection methods of ovarian cancer 
(OC) are still lacking and the disease continues to be one 
of the most deadly women’s neoplasms. The incidence rate 
in Europe is 9.9 and the age-standardised mortality rate is 
5.4 [1]. The biggest challenge in OC diagnosis is the detec-
tion of the disease in its early stages when the prognosis is 
favourable – for stage I OC (according to classification by 
International Federation of Gynaecology and Obstetrics 
– FIGO) the 5-year survival rate is around 90% whereas for 
advanced stages (FIGO III-IV) it decreases to 30% or less [2]. 
Current clinical practice involves serum cancer antigen 
125 (CA125) and human epididymis protein 4 (HE4) testing 
and performing a transvaginal ultrasound. Several algo-
rithms that combine clinical information, ultrasound fea-
tures and serum biomarker levels were developed to provide 
correct ovarian tumor differential diagnosis and achieved 
promising diagnostic accuracy for classic discrimination 
OC versus BOT (Tab. 1) but proved less effective for diag-
nosing early stage disease. As for the ultrasound models, 
most of the evidence derives from specialized ultrasound 
centers with particular expertise in this field and it is not 
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clear whether the same efficacy could be achieved in other 
centers [3]. Moreover, none of these methods is applicable 
for OC screening. 
Osteopontin has been recently intensively investigated 
as a potential OC biomarker. The meta-analysis by Hu et al. 
concluded that it could be a useful OC biomarker but nev-
ertheless emphasized the need for future studies to confirm 
its diagnostic potential in OC [7]. We have also previously 
investigated osteopontin as part of a biomarker panel of 
16 factors related to angiogenesis where it was identified 
as the best single marker for OC detection [8]. 
The purpose of this study was to investigate the diag-
nostic potential of selected multifactor tests in differential 
diagnosis of ovarian tumors with special emphasis on the 
role of osteopontin and early OC detection. To the best of 
our knowledge, this is the first study to provide such a broad 
analysis of the potential use of osteopontin as a part of 
multifactor diagnostic tests. 
MATHERIAL AND METHODS
Serum samples were collected from 122 patients qual-
ified for surgical treatment due to ovarian tumor in Gy-
necologic Oncology Department in 2014 and 2015. Blood 
samples were collected on the day before the surgery, in-
cubated for 30 minutes in room temperature to clot, and 
centrifuged for 15 minutes at 4000 rpm. Serum was then 
transferred to vials and stored at -80°C until analysis. 30 pa-
tients were disqualified due to meeting the exclusion criteria 
(non-epithelial OC or presence of any other malignancy 
currently or in anamnesis; n = 16) or incomplete clinical 
data recorded (n = 14). The remaining 92 patients were 
divided into 2 groups according to the histopathological 
result: OC and borderline ovarian tumors (n = 35 + 4) and 
BOT (n = 53). Table 2 presents the study group character-
istics. The age and BMI did not differ significantly between 
the groups. All patients were Caucasian females. Addition-
ally, the menopausal status was recorded. In women with 
previous hysterectomy, the menopausal age was set at the 
Polish average, i.e. 51 years old. 
Considering the fact that most sources recommend 
complete staging procedure if a borderline ovarian tumor 
is found, for the purpose of this study borderline ovar-
ian tumors were combined with the OC group. Borderline 
ovarian tumors constitute about 15% of all epithelial ovar-
ian tumors and occur in women approximately 10 years 
younger than OC. Although they are considered a distinct 
clinical entity than invasive OC, they can give implants in the 
omentum and peritoneum and share the staging system. The 
risk of recurrence after conservative surgery is significant 
(up to 27%) and invasive recurrences appear in up to 6% [9]. 
CA125 and HE4 concentrations were measured by ECLIA 
on Roche Cobas System in the Central Hospital Laboratory 
according to the manufacturer’s instructions. The level of 
osteopontin was measured as part of the immunoassay 
Bio-Plex Pro Human Cancer Biomarker Panel 1 (Bio-Rad, Her-
cules, CA, USA) using the flow cytometer Bio-Plex MAGPIX 
Table 1. Selected models and their performance in discrimination between benign and malignant tumors
Model Features Specificity [%] sensitivity [%] Reported AUC Reference
Risk of Ovarian Malignancy 
Algorithm (ROMA) Menopausal status, CA125, HE4 76.5 94.4 0.897 [4]
Risk of Malignancy Index (RMI) Menopausal status, CA125, ultrasoundscore 81.5 94.4 0.860–0.883 [5]
Assessment of Different NEoplasias 
in the adneXa (ADNEX)
Clinical variables, CA125, ultrasound 
features 96.5 71.3  0.954  [6]
Table 2. Study group characteristics
Ovarian 
cancer
Borderline 
tumors
Benign 
tumors
Number of samples 
[%] 35 (38.0) 4 (4.3) 53 (57.6)
Age [years] 
median (range) 59 (32–78) 48 (42–52) 41 (17–72)
BMI median  
(range)
25.2 
(18.5–38.4)
28.5  
(26.8–31.6)
24.2  
(17.8–39.9)
% of 
postmenopausal 77 25 28
FIGO stage, n [%]
I 8 (22.9) 4 (100) N/A
II 1 (2.9) 0 N/A
III 25 (71.4) 0 N/A
IV 1 (2.9) 0 N/A
Histopathological 
type, n [%]
Serous 15 (42.9) 2 (50.0) 10 (18.9)
Endometrioid 2 (5.7) 1 (25.0) 14 (26.4)
Mucinous 1 (2.9) 1 (25.0) 1 (1.9)
Clear cell 3 (8.6) 0 N/A
Undifferentiated 10 (28.6) 0 N/A
Non identified 4 (11.4) 0 N/A
Teratoma N/A N/A 10 (18.9)
Other N/A N/A 18 (34.0)
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(Bio-Rad, Hercules, CA, USA). The detailed methodology is 
described in our previous publication [8].  
Data analysis was performed using Statistica version 
13.1 (StatSoft Inc., Tulsa, OK, USA) and MetaboAnalyst ver-
sion 4.0, Biomarker Analysis module (www.metaboanalyst.
ca). Normality of data distribution was examined with the 
Shapiro-Wilk test. Differences in markers concentrations 
between the studied groups were evaluated using a t-test or 
Mann-Whitney U test. P-values ≤ 0.05 were considered  sta-
tistically significant. In order to calculate the discriminative 
ability of the investigated models, the univariate and multi-
variate receiver operating characteristic (ROC) curves were 
used. AUC (area under curve) of ROC were used to compare 
the diagnostic performance of the single markers (CA125, 
HE4 and osteopontin) and selected multifactor tests (ROMA, 
CA125 + HE4, ROMA + osteopontin, CA125 + HE4 + osteo-
pontin and CA125 + HE4 + osteopontin + age).
RESULTS
The results of the performed statistical analyses are 
summarized in Table 3.
As expected, all analysed single markers (CA125, HE4 and 
osteopontin) and multifactor tests (ROMA, CA125 + HE4, 
ROMA + osteopontin, CA125 + HE4 + osteopontin and 
CA125 + HE4 + osteopontin + age) significantly differenti-
ated the analysed groups.
In the whole cohort, the best single marker to distin-
guish OC and BOT (benign ovarian tumors) was HE4 (AUC 
of 0.939). Interestingly, the optimal cut off value was 
87.6 pmol/l whereas the laboratory cut off recommended 
by the manufacturer is 70 pmol/l for premenopausal wom-
en and 140 pmol/l for postmenopausal women. Among 
the multifactor tests, the highest AUC was obtained by 
ROMA + osteopontin. The addition of osteopontin to ROMA 
significantly improved the diagnostic performance of the 
test (AUC of 0.955 and 0.975, respectively). 
HE4 was identified as the best single marker in the group 
of premenopausal women and again the model ROMA + os-
teopontin obtained the highest AUC of 0.892 among the 
multifactor models. In postmenopausal women, the dis-
criminatory performance of all tests was clearly superior to 
that in premenopausal group. CA125 and the multifactor 
model ROMA obtained the best results (AUC of 0.995 and 
0.998, respectively). The model ROMA + osteopontin also 
achieved a comparably high AUC of 0.997. 
In the analysis based on the OC stage, the best single 
marker to differentiate between early stage OC and BOTs 
was osteopontin (AUC of 0.863) whereas for advanced stage 
Table 3. Discriminatory value of different serum markers and multivariate models in differential diagnosis of ovarian tumors. The best AUC values 
obtained for single markers and for multimarker models are bolded
Marker
Group
CA125 
[U/mL]
HE4 
[pmol/l]
osteopontin 
[pg/mL] ROMA
CA125 
+ HE4
CA125 
+ HE4 + 
osteopontin
ROMA + 
osteopontin
CA125 + HE4 
+ osteopontin 
+ age
OC (incl. 
borderline) vs 
BOT — total
p-value < 0.001 < 0.001 < 0.001 < 0.001
AUC 0.933 0.939 0.825 0.955 0.946 0.957 0.975 0.951
Cut-off 71.4 87.6 44500.0 28.0
Sens/spec 0.85/0.91 0.87/0.96 0.72/0.79 0.90/0.96
OC (incl. 
borderline) vs 
BOT — pre-
menopausal 
women
p-value < 0.001 < 0.001 0.016 0.001
AUC 0.832 0.866 0.741 0.828 0.788 0.823 0.892 0.800
Cut-off 71.4 59.7 41446.8 11.3
Sens/spec 0.73/0.87 0.83/0.79 0.64/0.76 0.82/0.79
OC (incl. 
borderline) vs 
BOT— post-
menopausal 
women
p-value < 0.001 < 0.001 < 0.001 < 0.001
AUC 0.995 0.962 0.848 0.998 0.995 0.978 0.997 0.971
Cut-off 53.85 104.9 44842.0 45.6
Sens/spec 0.96/1.0 0.89/0.93 0.79/0.80 0.96/1.0
FIGO stage 
I-II (incl. 
borderline) 
OC vs BOT
p-value < 0.001 < 0.001 < 0.001 < 0.001
AUC 0.833 0.840 0.863 0.865 0.783 0.872 0.895 0.870
Cut-off 63.16 59.67 41435.1 15.1
Sens/spec 0.75/0.87 0.83/0.75 0.92/0.70 0.83/0.83
FIGO stage 
III-IV (incl. 
borderline)  
OC vs BOT
p-value < 0.001 < 0.001 < 0.001 < 0.001
AUC 0.977 0.985 0.808 0.988 0.998 0.992 0.990 0.976
Cut-off 107.55 104.9 45300.9 56.5
Sens/spec 0.93/0.94 0.96/0.98 0.70/0.81 0.96/0.98
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disease HE4 obtained the highest AUC of 0.985. In multifac-
tor models, the addition of osteopontin to ROMA again 
improved the diagnostic performance of the test in the 
early stage OC group (from AUC = 0.865 to AUC = 0.895). 
The best marker distinguishing advanced stage OC and BOTs 
was HE4 and, consistently, the best multifactor model in this 
comparison was CA125 + HE4.
DISCUSSION
Osteopontin was first described as a glycoprotein se-
creted by osteoblasts in bone but it was found to be involved 
in various other cellular processes, such as inflammation, 
immune response, angiogenesis and finally tumorigenesis 
[10]. It was confirmed to be overexpressed in several malig-
nancies including cervical, breast, prostate, colorectal, lung 
and pancreatic cancer [11]. In OC osteopontin was shown 
to promote the OC cell growth in vitro and in vivo and to 
increase the survival of OC cells under stress conditions [12]. 
Other studies proved its role in OC cells migration and inva-
sion [13] as well as identified osteopontin as an independent 
predictor of poor prognosis [14]. Consequently, osteopontin 
was recently intensively investigated as a potential novel 
OC biomarker. Nevertheless, our study provides additional 
information on the performance of osteopontin in the se-
lected groups and in multimarker diagnostic tests.
Two meta-analyses focused on the role of osteopontin in 
OC. A meta-analysis by Lan et al. reports the overall diagnos-
tic sensitivity and specificity of osteopontin as a diagnostic 
test for OC of 0.766 (95% CI 0.685–0.831) and 0.897 (95% CI 
0.849–0.931), respectively. For the two-marker test based on 
osteopontin and CA125, the sensitivity and specificity were 
0.871 (95% CI 0.788–0.924) and 0.881 (95% CI 0.837–0.914), 
respectively. The meta-analysis comprised studies compar-
ing OC, BOTs and healthy controls and concludes that osteo-
pontin is a useful biomarker to be applied in OC screening 
tests and a promising adjunct to CA125 [15]. The second 
meta-analysis by Hu et al. reports the overall sensitivity and 
specificity of osteopontin to be 0.66 (95% CI, 0.51–0.78) and 
0.88 (95% CI, 0.78–0.93), respectively, and the AUC of ROC of 
0.85 (95% CI, 0.81–0.88) [7]. This study also sees osteopontin 
as a useful biomarker in OC diagnosis, however empha-
sizes the need for a rigorously designed study to confirm 
it. Finally, a study similar to ours on 114 women analysing 
the role of osteopontin in differential diagnosis of ovar-
ian tumors reports its overall sensitivity of 0.72, specificity 
of 0.89 and AUC of 0.812 at a cut-off level of 28000 pg/mL 
[16]. All the above-mentioned results correspond with our 
findings. None of these studies, however, conducted such 
a broad analysis of the potential use of osteopontin as a part 
of multifactor diagnostic tests. 
One of the main challenges in diagnosing OC is how to 
detect the disease in its early stages. In the United Kingdom 
Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), 
in which over 200000 post-menopausal women underwent 
screening using annual CA125 measurements interpret-
ed by the Risk of Ovarian Cancer Algorithm (ROCA), less 
than a half of the OCs detected by screening were in early 
stages (FIGO I-II) [17] with most women not diagnosed until 
the disease is in its advanced stages. The United Kingdom 
Collaborative Trial of Ovarian Cancer Screening (UKCTOCS. 
Hence, there is an urgent need for new early detection strat-
egies. In our study in the FIGO stage I-II group osteopontin 
was identified as the best single marker and combining it 
with ROMA resulted in further improvement of the diag-
nostic performance of the test in the early stage OC group. 
These results indicate that osteopontin could be a valuable 
early stage OC marker.
Another difficulty in diagnosing OC is the group of 
pre-menopausal women. The performance of most of the 
markers is much poorer in this age group as compared 
to older women. In our study, the addition of osteopon-
tin did not alter the diagnostic performance of ROMA test 
in post-menopausal women whereas in pre-menopausal 
group the AUC was significantly improved. This leads to 
a conclusion that osteopontin is a promising marker princi-
pally for the population of pre-menopausal women. 
Additionally, some studies point at the potential use-
fulness of osteopontin in OC treatment monitoring and 
diagnosing recurrent disease, especially in those patients 
with CA125 concentrations within the reference value. Those 
studies report that the rise in the levels of osteopontin, 
which correlated with the disease recurrence, preceded the 
rise in CA125 even by 3 months [18, 19].
Due to a limited number of samples this study did not 
compare the diagnostic performance of the models be-
tween OC type I and II as well as between different histo-
pathological types of OC. 
CONCLUSIONS
Osteopontin significantly improved the diagnostic 
performance of the ROMA test in both, pre-menopausal 
women and in early stage OC. These results indicate that 
it is a perfect candidate to become a valuable early stage 
OC marker, especially as a part of multimarker tests. Fur-
ther research with rigorous study design and larger study 
groups focusing on premenopausal women and/or on bor-
derline/early-stage OC is needed to confirm its diagnostic 
potential and optimal use.
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